Follicular fluid thyroid autoantibodies, thyrotropin, free thyroxine levels and assisted reproductive technology outcome

Medenica, Sanja; Garalejić, Eliana; Arsić, Biljana; Medjo, Biljana; Jovic, Dragana Bojovic; Abazović, Džihan; Vuković, Rade; Žarković, Miloš

doi:10.1371/journal.pone.0206652

Cited by 29 publications

(37 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fact that when analyzing the four selected parameters in the IVF protocols, definitive conclusion about the effect of antithyroid antibodies and subclinical hypothyroidism on ART outcomes cannot be made, worth attention. For instance, Zhong et al [11] reported lower fertilization rate, implantation rate and pregnancy rate following IVF-ET in women with TAI, while Medenica et al [10] did not reveal any decrease in fertilization rate. Perhaps because in their group of subjects, some women also underwent ICSI treatment.…”

Section: Ivf/icsi Outcomesmentioning

confidence: 98%

“…Pregnancies rates per initiated cycle and per embryo-transfer cycle were significantly different between the TAI positive and the TAI negative group (30.8% versus 61.5%), p ¼ .026 and (34.8% versus 66.7%), p ¼ .029, respectively. Multivariate analysis showed that TAI positive women had significantly less chance to achieve pregnancy (OR 0.036, 95% CI [0.004-0.347], p ¼ .004) [10].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does subclinical hypothyroidism and/or thyroid autoimmunity influence the IVF/ICSI outcome? Review of the literature

Safarian

Gzgzyan

Lyailya

et al. 2019

Gynecological Endocrinology

View full text Add to dashboard Cite

While overt hypothyroidism is a well-known risk factor for infertility, the association of subclinical hypothyroidism (SCH) or thyroid autoimmunity and reproductive failure has been still not elucidated. In this literature review, the current data on the effect of SCH and/or thyroid autoimmunity and human reproduction is presented. The main ART outcome measures are as follows: number of oocytes retrieved, fertilization rate, implantation rate, clinical pregnancy rate per embryo transfer, embryo quality, miscarriage rate, and live birth rate. Current guidelines on the management of women with SCH and/or thyroid autoimmunity undergoing ART cycles will be presented in this review.

show abstract

Section: Ivf/icsi Outcomesmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Does subclinical hypothyroidism and/or thyroid autoimmunity influence the IVF/ICSI outcome? Review of the literature

Safarian

Gzgzyan

Lyailya

et al. 2019

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…T hyroid hormones (TH) may interact directly with oocyte physiology via the presence of TH receptors in granulosa/cumulus cells and indirectly by facilitating the actions of the follicle stimulation hormone (FSH) on granulosa cells in terms of the steroidogenic activity, cellular morphology, the expression of the LH/CG receptor, and by protecting them against apoptosis via the PI3-K pathway (1)(2)(3). Thyrotropin (TSH) receptors are also present on human ovarian tissue and granulosa cells, but their function needs to be investigated further (4).TH and thyroid antibodies are present in follicular fluid (FF) in concentrations that correlate with those in the serum, and recently, it has been suggested that thyroid peroxidase (TPO) might be present in granulosa cells (5)(6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Thyroid Disorders and In Vitro Outcomes of Assisted Reproductive Technology: An Unfortunate Combination?

Poppe

Autin

Veltri

et al. 2020

Thyroid

View full text Add to dashboard Cite

Background: The impact of thyroid disorders on in vitro outcomes of assisted reproductive technology (ART) remains controversial. Therefore, the aim of our study was to investigate whether thyroid peroxidase antibodies (TPO-Abs)/thyroid autoimmunity (TAI) or thyroid function (serum thyrotropin [TSH])/subclinical hypothyroidism are associated with an altered number of oocyte retrieval (NOR), fertilization rate (FR), and embryo quality (EQ). Methods: Cross-sectional study in 279 women in a single center, comprising 297 cycles and 1168 embryos. In vitro data (NOR, FR, and EQ) were documented in two groups; one according to thyroid function in women without TAI (TSH £2.5 and >2.5 mIU/L) and one according to the presence/absence of TAI (determined by TPO-Abs). EQ was evaluated according to international criteria and classified as excellent/good and poor. Women treated with levothyroxine (LT4) were excluded. Furthermore, the impact of thyroid parameters on outcomes, normal NOR (>6 or 8) and high FR (>60%), was verified in a multivariable logistic regression model. Results: In women without TAI, 27% had TSH levels >2.5 mIU/L, the prevalence of TAI was 8%, and overall, 6% of women had TSH levels >4.2 mIU/L. NOR, FR, and EQ were comparable between study groups. In the regression analysis, women aged ‡30 years and receiving a high ovarian stimulation dosage (>2300 IU/cycle) had lower rates of normal NOR (odds ratio [OR] 0.18 [95% confidence interval, CI 0.04-0.72]; p = 0.016 and OR 0.17 [CI 0.06-0.48]; p < 0.001, respectively). Conclusions: Our results do not suggest an impact of thyroid antibodies/autoimmunity and (dys)function on ART in vitro outcomes.

show abstract

“…Based on the studies published since the 2017 ATA Guidelines, no alteration of the Guidelines are indicated, but further investigation is warranted. Five studies examined the association between thyroid autoimmunity and outcomes of ART (46)(47)(48)(49)(50). Two studies reported a negative association between thyroid autoimmunity and outcomes after ART (48)(49)(50).…”

Section: C) Autoimmunity and Preterm Delivery (Question 19)mentioning

confidence: 99%

“…Five studies examined the association between thyroid autoimmunity and outcomes of ART (46)(47)(48)(49)(50). Two studies reported a negative association between thyroid autoimmunity and outcomes after ART (48)(49)(50). In a retrospective cohort study of 300 However, three studies reported no difference in ART outcomes between women with and without thyroid autoimmunity (46,47).…”

Section: C) Autoimmunity and Preterm Delivery (Question 19)mentioning

confidence: 99%

The Need for Dynamic Clinical Guidelines: A Systematic Review of New Research Published After Release of the 2017 ATA Guidelines on Thyroid Disease During Pregnancy and the Postpartum

2020

View full text Add to dashboard Cite

Background: The American Thyroid Association Guidelines on Thyroid Disease During Pregnancy and the Postpartum (ATA Guidelines) were published in 2017, with an update not expected for another 5 years. Since release of the 2017 ATA Guidelines, greater than 500 articles have been published in the field. Furthermore, there are presently 14 prospective, interventional trials in progress registered at Clinicaltrials.gov Static guidelines updated every 5-7 years fail to provide timely evidence-based guidance to practicing clinicians. Consequently, guideline development should move toward the creation of dynamic documents. The present article reviews the literature published since the 2017 ATA Guidelines, both to benefit clinicians in practice and to make the case for Dynamic ATA Guidelines. Methods: Using the search terms "thyroid" and "pregnancy," a systematic review of literature published in Pubmed from 3/1/2017 to 12/31/2018 was conducted. The titles and/or abstracts of all articles were reviewed. All articles were classified by subject headings used in the 2017 ATA Guidelines. English-text articles classified under "hypothyroidism" or "thyroid autoimmunity" were examined in full-text. Using the questions and recommendations put forth by the previous ATA Guidelines, relevant articles were selected for discussion in this review. Results: At the time of the search, 659 unique articles on "thyroid and pregnancy" were identified, including 66 original studies on hypothyroidism and 26 on thyroid autoimmunity. Of these, 26 studies on hypothyroidism and 18 studies on thyroid autoimmunity were selected for inclusion in this review based on specific questions in the 2017 ATA Guidelines. Based on these 44 articles, we propose two specific changes to the 2017 ATA Guidelines. Conclusion: Based on new research, we recommend the 2017 ATA Guidelines be updated to recommend against treating thyroid antibody-negative women diagnosed Dong et al. Thyroid in Pregnancy Since 2017 with subclinical hypothyroidism in the second trimester or later; to reflect new, moderate-quality evidence supporting the treatment of thyroid peroxidase antibody-negative women with elevated thyroid stimulating hormone levels in the first trimester or earlier; and to recommend against treatment of euthyroid, thyroid peroxidase antibody-positive women undergoing assisted reproductive technology. Transitioning to a Dynamic ATA Guidelines would allow for these and future recommendations to be implemented in real time.

show abstract

Follicular fluid thyroid autoantibodies, thyrotropin, free thyroxine levels and assisted reproductive technology outcome

Cited by 29 publications

References 43 publications

Does subclinical hypothyroidism and/or thyroid autoimmunity influence the IVF/ICSI outcome? Review of the literature

Does subclinical hypothyroidism and/or thyroid autoimmunity influence the IVF/ICSI outcome? Review of the literature

Thyroid Disorders and In Vitro Outcomes of Assisted Reproductive Technology: An Unfortunate Combination?

The Need for Dynamic Clinical Guidelines: A Systematic Review of New Research Published After Release of the 2017 ATA Guidelines on Thyroid Disease During Pregnancy and the Postpartum

Contact Info

Product

Resources

About